^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD69 (CD69 Molecule)

    i
    Other names: CD69 Molecule, CLEC2C, CD69 Antigen (P60, Early T-Cell Activation Antigen), Early T-Cell Activation Antigen P60, Leukocyte Surface Antigen Leu-23, Early Activation Antigen CD69, BL-AC/P26, GP32/28, MLR-3, AIM, EA1, C-Type Lectin Domain Family 2, Member C, Activation Inducer Molecule (AIM/CD69), C-Type Lectin Domain Family 2 Member C, Early Lymphocyte Activation Antigen, Activation Inducer Molecule, CD69 Antigen, CD69
    5d
    Peptide hydrogel boosts the cytotoxic and metabolic fitness of Vγ9Vδ2 T cells in melanoma immunotherapy. (PubMed, Front Immunol)
    SAM.1 hydrogel acted as a two-in-one scaffold, controlled release and an immunomodulatory agent, to enhance the persistence and antitumor function of Vγ9Vδ2 T cells. This strategy provided a new paradigm for γδ T-cell-based immunotherapy in melanoma.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • ITGAE (Integrin Subunit Alpha E) • ITGAX (Integrin Subunit Alpha X)
    5d
    H3K4 methylation of CALB2 facilitates immune evasion and chemoradiotherapy resistance in cholangiocarcinoma through KRT7-mediated PD-L1 upregulation. (PubMed, Int Immunopharmacol)
    Notably, CALB2 knockdown significantly sensitized CCA tumors to gemcitabine plus radiotherapy, an effect attenuated by KRT7 overexpression. These findings define a novel H3K4 methylation/CALB2/calcium/NF-κB/KRT7/PD-L1 signaling axis that drives immune suppression and therapy resistance in CCA, highlighting its potential as a multi-target strategy for combined immunotherapy and chemoradiotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • KRT7 (Keratin-7) • CALB1 (Calbindin 1) • CALB2 (Calbindin 2)
    |
    PD-L1 expression
    |
    gemcitabine
    9d
    Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma. (PubMed, Haematologica)
    Both BCMA and CD307e were more highly expressed on BM plasma-cells than CTPCs. This study is among the first to provide a comprehensive phenotypic characterisation of CD56+ CTPCs across the MM spectrum, including checkpoint and chemokine receptors, treated disease cases, and paired BM samples for NDMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR6 (C-C Motif Chemokine Receptor 6) • HLA-C (Major Histocompatibility Complex, Class I, C) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    14d
    Circulating exhausted CD8+ effector memory cells differentiate immune checkpoint inhibitor-induced liver injury from other acute immune-mediated liver injuries. (PubMed, J Immunother Cancer)
    We have shown that circulating CD8+ T cells provide a potential biomarker to distinguish ChILI from DILI and AIH, and highlight different mechanistic pathways between ChILI and other immune-mediated liver injuries.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD69 (CD69 Molecule) • CD27 (CD27 Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    15d
    Personalized medicine in triple-negative breast cancer: combining neoantigen vaccination and genomic profiling in a patient undergoing neoadjuvant chemotherapy. (PubMed, Front Oncol)
    The observation of immune responses to both vaccine and non-vaccine neoantigens raises the possibility of epitope spreading, though this finding requires cautious interpretation due to pre-existing immune responses. As a single-patient case study, these results remain preliminary and must be validated in larger cohorts.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NF1 (Neurofibromin 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • CD40LG (CD40 ligand)
    |
    TP53 mutation
    17d
    Breast cancer tumor immune microenvironment landscape identifies prognostic risk genes and potential drugs. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
    Furthermore, fourteen candidate drugs targeting this network were predicted, and structural analogs of Lumacaftor and Ivosidenib showed promising docking affinities to CD1C and CXCR3, respectively. These findings provide preliminary insights into TIM-associated prognostic pathways and suggest candidate compounds for further investigation in BRCA.
    Journal
    |
    BRCA (Breast cancer early onset) • CD69 (CD69 Molecule) • CD40LG (CD40 ligand) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CD1C (CD1c Molecule)
    |
    Tibsovo (ivosidenib)
    25d
    Characteristics of NK cells activation following IL-12, IL-15, IL-18 cytokines stimulation for preclinical purposes. (PubMed, Sci Rep)
    NK cells activated with IL-12/IL-15, and IL-12/IL-15/IL-18 co-cultured with MHC- tumor cells, and in each cytokine combination with MHC+ tumor cells caused proliferation inhibition and lysis of tumor cells. Activation of NK cells, particularly with the combination of IL-12/IL-15/IL-18 cytokines, shows potential clinical relevance in adoptive cell therapy.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IL18 (Interleukin 18) • CCL3 (C-C Motif Chemokine Ligand 3) • IL15 (Interleukin 15)
    27d
    Metabolic Tracing Reveals IL-2 Driven Glutaminolysis and De Novo Pyrimidine Synthesis in Human Natural Killer Cells. (PubMed, J Biol Chem)
    The data indicate that glutamine is a key nutrient taken up by human NK cells, and that IL-2 drives glutaminolysis. Subsequent glutamate is used to support the TCA cycle, generating energy and providing intermediates for de novo pyrimidine synthesis.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule) • IL2 (Interleukin 2)
    27d
    Photodynamic priming with Vitamin D and ALA-based PDT induces intratumoral immune cell recruitment and signaling pathway activation in cutaneous squamous cell carcinoma. (PubMed, Cancer Immunol Immunother)
    Collectively, these findings demonstrate that VitD reprograms the immune response to PDT in SCC, enhancing cytotoxic immunity while limiting immunosuppressive features. This combination suggests an immune-priming strategy that might be considered, together with immune checkpoint blockade, for SCC and other immunosuppressive cancers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD69 (CD69 Molecule) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    28d
    Distinct NK Cell Signatures Define Prognosis in HPV-Positive Versus HPV-Negative Head and Neck Cancer. (PubMed, Cancers (Basel))
    The CX3CR1+KLRB1dim subset represents a candidate prognostic biomarker in HPV+ disease, and the CLEC2-KLRB1 axis is a targetable immune evasion mechanism in HPV- HNSCC. These insights support the development of HPV-stratified immunotherapies; however, clinical translation requires validation in large, prospectively designed, subsite-matched cohorts to disentangle HPV-specific effects from anatomical site-dependent immune contextures.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    1m
    Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors. (PubMed, Sci Rep)
    These findings demonstrate that αGD2 × αCD3 BiPE effectively enhances T-cell activity and anti-tumor responses in a GD2-dependent manner. This study highlights its potential as a promising therapeutic strategy for GD2-overexpressing cancers, warranting further optimization and evaluation across diverse tumor types.
    Journal • IO biomarker
    |
    IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule)